Pharming and Baxter collaborate in angioedema

Pharming (EASD:PHAR) and BAX will develop PHAR's recombinant human C1 inhibitor to treat hereditary angioedema, a disease that causes swelling in organs and tissues. PHAR will receive license fees and...